KBC Group: Publication of transparency notification(s) received by KBC Group NV
(art. 14, 1st section of the Act of 2 May 2007 concerning the disclosure of significant participations)
Summary of the notification(s)
KBC Group NV has received an updated transparency notification on 27 May 2025, which states that FMR has a stake of 3.29% in KBC Group (total voting rights and equivalent financial instruments). The reason for the update is a crossing of the 3%- reporting threshold.
Content of the notification(s)
The notification(s) contain(s) following information:
Reason for the notification(s): 'Acquisition or disposal of voting securities or voting rights'
Notification(s) by: FMR LLC.
Persons subject to the notification requirement: see annex
Date(s) on which the 3% threshold is crossed: 21 May 2025.
Threshold that is crossed: KBC Group's Articles of Association set a notification threshold of 3% of the total number of voting rights. In addition, the legal thresholds of 5% or any multiple thereof also apply.
Denominator (number of shares KBC Group NV): 417 544 151
Notified details: see annex.
Chain of controlled undertakings through which the holding is effectively held:See '11: Full chain of controlled undertakings through which the holding is effectively held' in the PDF-file(s) on www.kbc.com (see below).
The relevant notification(s) is (are) available at www.kbc.com > Investor relations > Shareholder information > Shareholder structure.
For more information, please contact:
Kurt De Baenst, General Manager Investor Relations, KBC GroupE-mail: IR4U@kbc.com
Katleen Dewaele, General Manager Corporate Communication, KBC Grouppressofficekbc@kbc.be
Attachment
20250602-pb-trp-en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Share Buyback Transaction Details June 5 – June 11, 2025
PRESS RELEASE Share Buyback Transaction Details June 5 – June 11, 2025 Alphen aan den Rijn – June 12, 2025 - Wolters Kluwer (Euronext: WKL), a global leader in professional information solutions, software and services, today reports that it has repurchased 222,303 of its own ordinary shares in the period from June 5, 2025, up to and including June 11, 2025, for €34.4 million and at an average share price of €154.85. These repurchases are part of the share buyback program announced on February 26, 2025, under which we intend to repurchase shares for up to € 1 billion during 2025. The cumulative amounts repurchased in the year to date under this program are as follows: Share Buyback 2025 Period Cumulative shares repurchased in period Total consideration(€ million) Average share price(€) 2025 to date 2,972,609 461.9 155.38 For the period starting May 8, 2025, up to and including July 28, 2025, we have engaged third parties to execute €350 million of buybacks on our behalf, within the limits of relevant laws and regulations (in particular Regulation (EU) 596/2014) and the company's Articles of Association. Shares repurchased are added to and held as treasury shares and will be used for capital reduction purposes through share cancelation. Further information is available on our website: Download the share buyback transactions excel sheet for detailed individual transaction information. Weekly reports on the progress of our share repurchases. Overview of share buyback programs. For more information about Wolters Kluwer, please visit: ### About Wolters Kluwer Wolters Kluwer (EURONEXT: WKL) is a global leader in information solutions, software and services for professionals in healthcare; tax and accounting; financial and corporate compliance; legal and regulatory; corporate performance and ESG. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with technology and services. Wolters Kluwer reported 2024 annual revenues of €5.9 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 21,900 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands. Wolters Kluwer shares are listed on Euronext Amsterdam (WKL) and are included in the AEX, Euro Stoxx 50 and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt (ADR) program. The ADRs are traded on the over-the-counter market in the U.S. (WTKWY). For more information, visit follow us on LinkedIn, Facebook, YouTube and Instagram. Media Investors/Analysts Stefan Kloet Meg Geldens Associate Director Vice President Global Communications Investor Relations press@ ir@ Forward-looking Statements and Other Important Legal InformationThis report contains forward-looking statements. These statements may be identified by words such as 'expect', 'should', 'could', 'shall' and similar expressions. Wolters Kluwer cautions that such forward-looking statements are qualified by certain risks and uncertainties that could cause actual results and events to differ materially from what is contemplated by the forward-looking statements. Factors which could cause actual results to differ from these forward-looking statements may include, without limitation, general economic conditions; conditions in the markets in which Wolters Kluwer is engaged; conditions created by pandemics; behavior of customers, suppliers, and competitors; technological developments; the implementation and execution of new ICT systems or outsourcing; and legal, tax, and regulatory rules affecting Wolters Kluwer's businesses, as well as risks related to mergers, acquisitions, and divestments. In addition, financial risks such as currency movements, interest rate fluctuations, liquidity, and credit risks could influence future results. The foregoing list of factors should not be construed as exhaustive. Wolters Kluwer disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Elements of this press release contain or may contain inside information about Wolters Kluwer within the meaning of Article 7(1) of the Market Abuse Regulation (596/2014/EU). Trademarks referenced are owned by Wolters Kluwer N.V. and its subsidiaries and may be registered in various countries. Attachment 2025.06.12 Share Buyback Transactions Jun 5 - 11 2025Sign in to access your portfolio
Yahoo
2 days ago
- Yahoo
GeNeuro SA Announces an Extraordinary Shareholders' Meeting on June 30, 2025
GENEVA, June 10, 2025--(BUSINESS WIRE)--Regulatory News: GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, announces that it will hold an extraordinary shareholders' meeting on June 30, 2025. As previously disclosed, GeNeuro is subject to a definitive debt-restructuring moratorium granted by the Geneva Tribunal of First Instance on 26 May 2025. In this context, the Company is not in a position to finalize and present its audited annual accounts for the financial year ending 31 December 2024. Consequently, it cannot hold its Ordinary Annual General Meeting within six months of year-end, as required under Swiss corporate law. Pursuant to the Company's Articles of Association and applicable Swiss legal provisions, the mandates of the current members of the Board of Directors will expire on 30 June 2025. To ensure continuity of governance, the Extraordinary General Meeting has been convened to vote on the re-election of the Board members, of the Chairman, of the Remuneration Committee, and of the Independent Proxy until the next Annual General Meeting can be held. The notice to the meeting is published today in the Swiss Official Gazette of Commerce. About GeNeuro GeNeuro's mission is to develop safe and effective treatments against neurological disorders and autoimmune diseases, such as multiple sclerosis, by neutralizing causal factors encoded by HERVs, which represent 8% of human DNA. GeNeuro is based in Geneva, Switzerland and has R&D facilities in Lyon, France. For more information, visit: Disclaimer This press release contains certain forward - looking statements and estimates concerning GeNeuro's financial condition, operating results, strategy, projects and future performance and the markets in which it operates. Such forward-looking statements and estimates may be identified by words, such as "anticipate," "believe," "can," "could," "estimate," "expect," "intend," "is designed to," "may," "might," "plan," "potential," "predict," "objective," "should," or the negative of these and similar expressions. They incorporate all topics that are not historical facts. Forward looking statements, forecasts and estimates are based on management's current assumptions and assessment of risks, uncertainties and other factors, known and unknown, which were deemed to be reasonable at the time they were made but which may turn out to be incorrect. Events and outcomes are difficult to predict and depend on factors beyond the company's control. Consequently, the actual results, financial condition, performances and/or achievements of GeNeuro or of the industry may turn out to differ materially from the future results, performances or achievements expressed or implied by these statements, forecasts and estimates. Owing to these uncertainties, no representation is made as to the correctness or fairness of these forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates speak only as of the date on which they are made, and GeNeuro undertakes no obligation to update or revise any of them, whether as a result of new information, future events or otherwise, except as required by law.. View source version on Contacts GeNeuro Jesús Martin-GarciaChairman and CEOinvestors@ Sign in to access your portfolio
Business Wire
2 days ago
- Business Wire
GeNeuro SA Announces an Extraordinary Shareholders' Meeting on June 30, 2025
GENEVA--(BUSINESS WIRE)--Regulatory News: GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, announces that it will hold an extraordinary shareholders' meeting on June 30, 2025. As previously disclosed, GeNeuro is subject to a definitive debt-restructuring moratorium granted by the Geneva Tribunal of First Instance on 26 May 2025. In this context, the Company is not in a position to finalize and present its audited annual accounts for the financial year ending 31 December 2024. Consequently, it cannot hold its Ordinary Annual General Meeting within six months of year-end, as required under Swiss corporate law. Pursuant to the Company's Articles of Association and applicable Swiss legal provisions, the mandates of the current members of the Board of Directors will expire on 30 June 2025. To ensure continuity of governance, the Extraordinary General Meeting has been convened to vote on the re-election of the Board members, of the Chairman, of the Remuneration Committee, and of the Independent Proxy until the next Annual General Meeting can be held. The notice to the meeting is published today in the Swiss Official Gazette of Commerce. About GeNeuro GeNeuro's mission is to develop safe and effective treatments against neurological disorders and autoimmune diseases, such as multiple sclerosis, by neutralizing causal factors encoded by HERVs, which represent 8% of human DNA. GeNeuro is based in Geneva, Switzerland and has R&D facilities in Lyon, France. For more information, visit: Disclaimer This press release contains certain forward - looking statements and estimates concerning GeNeuro's financial condition, operating results, strategy, projects and future performance and the markets in which it operates. Such forward-looking statements and estimates may be identified by words, such as 'anticipate,' 'believe,' 'can,' 'could,' 'estimate,' 'expect,' 'intend,' 'is designed to,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'objective,' 'should,' or the negative of these and similar expressions. They incorporate all topics that are not historical facts. Forward looking statements, forecasts and estimates are based on management's current assumptions and assessment of risks, uncertainties and other factors, known and unknown, which were deemed to be reasonable at the time they were made but which may turn out to be incorrect. Events and outcomes are difficult to predict and depend on factors beyond the company's control. Consequently, the actual results, financial condition, performances and/or achievements of GeNeuro or of the industry may turn out to differ materially from the future results, performances or achievements expressed or implied by these statements, forecasts and estimates. Owing to these uncertainties, no representation is made as to the correctness or fairness of these forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates speak only as of the date on which they are made, and GeNeuro undertakes no obligation to update or revise any of them, whether as a result of new information, future events or otherwise, except as required by law..
